184 related articles for article (PubMed ID: 10483575)
1. [High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
Arnold G; Kupsch A
Nervenarzt; 1999 Aug; 70(8):742-4. PubMed ID: 10483575
[TBL] [Abstract][Full Text] [Related]
2. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Facca A; Sanchez-Ramos J
Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
[No Abstract] [Full Text] [Related]
3. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Block G; Liss C; Reines S; Irr J; Nibbelink D
Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
[TBL] [Abstract][Full Text] [Related]
6. Adjuncts to levodopa therapy: dopamine agonists.
Poewe W
Neurology; 1998 Jun; 50(6 Suppl 6):S23-6; discussion S44-8. PubMed ID: 9633683
[TBL] [Abstract][Full Text] [Related]
7. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
8. Switching from pergolide to pramipexole in patients with Parkinson's disease.
Hanna PA; Ratkos L; Ondo WG; Jankovic J
J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
[TBL] [Abstract][Full Text] [Related]
9. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Grosset K; Needleman F; Macphee G; Grosset D
Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
[TBL] [Abstract][Full Text] [Related]
10. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Zimmerman TR; Sage JI; Lang AE; Mark MH
Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
[TBL] [Abstract][Full Text] [Related]
11. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
Pinter MM; Rutgers AW; Hebenstreit E
J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
[TBL] [Abstract][Full Text] [Related]
12. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
Ludin HP; Surber Ch
Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Pinter MM; Pogarell O; Oertel WH
J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
[TBL] [Abstract][Full Text] [Related]
15. Initiating therapy for Parkinson's disease.
Silver DE; Ruggieri S
Neurology; 1998 Jun; 50(6 Suppl 6):S18-22; discussion S44-8. PubMed ID: 9633682
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
17. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Davis TL; Roznoski M; Burns RS
Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
[TBL] [Abstract][Full Text] [Related]
18. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Wolters EC; Horstink MW; Roos RA; Jansen EN
Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
[No Abstract] [Full Text] [Related]
19. Treatment of Parkinson's disease should begin with a dopamine agonist.
Montastruc JL
Mov Disord; 2000 Mar; 15(2):361-2. PubMed ID: 10752600
[No Abstract] [Full Text] [Related]
20. Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
Coon EA; Laughlin RS
J Headache Pain; 2012 Apr; 13(3):255-7. PubMed ID: 22322657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
